This shift is supported by growing evidence that GLP-1s deliver multi-system benefits, from improved metabolic markers to reductions in cardiovascular risk, kidney disease progression, and other comorbidities common in people with type 2 diabetes or obesity
5.4% after 12 hr, n=205
It is not a standalone solution but works best as part of a comprehensive weight management plan
Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial
To better understand the human side of the GLP-1 divide, The Health Management Academy surveyed 1,827 Americans in November 2025 to capture the real-world impact of the GLP-1 divide, highlighting the emotional, social, and financial toll it takes across different incomes and between men and women
Within two years, she developed severe stomach paralysis